Regenxbio (FRA:RB0) E10: €-2.51 (As of Mar. 2026)


FRA:RB0 Regenxbio Inc FRA:RB0
55 GF Score
Price €13.00
GF Value €12.61
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is Regenxbio E10?

Regenxbio FRA:RB0 +12.26% 55 E10 is €-2.51 as of Mar. 2026. GuruFocus rates FRA:RB0 with a GF Score™ of 55/100 and a GF Value™ of €12.61 (Fairly Valued). The stock has 9 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Regenxbio's adjusted earnings per share data for the three months ended in Mar. 2026 was €-1.488. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-2.51 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-07), Regenxbio's current stock price is €13.00. Regenxbio's E10 for the quarter that ended in Mar. 2026 was €-2.51. Regenxbio's Shiller PE Ratio of today is .


Regenxbio  (FRA:RB0) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Regenxbio E10 Related Terms


Regenxbio E10 Historical Data

* Premium members only.

The historical data trend for Regenxbio's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenxbio E10 Chart

Regenxbio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -2.50 -2.40

Regenxbio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.72 -2.46 -2.39 -2.40 -2.51

FRA:RB0 vs ALT, ASMB, CTNM: E10 Comparison

For the Biotechnology subindustry, Regenxbio's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenxbio Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenxbio's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Regenxbio's Shiller PE Ratio falls into.


FRA:RB0
55GF Score
Regenxbio Inc FRA:RB0
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regenxbio E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Regenxbio's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-1.488/330.2130*330.2130
=-1.488

Current CPI (Mar. 2026) = 330.2130.

Regenxbio Quarterly Data

per share eps CPI Adj_EPS
201606 -0.490 241.018 -0.671
201609 -0.615 241.428 -0.841
201612 -0.702 241.432 -0.960
201703 -0.767 243.801 -1.039
201706 -0.418 244.955 -0.563
201709 -0.562 246.819 -0.752
201712 -0.431 246.524 -0.577
201803 2.465 249.554 3.262
201806 0.257 251.989 0.337
201809 -0.480 252.439 -0.628
201812 0.097 251.233 0.127
201903 -0.788 254.202 -1.024
201906 -0.035 256.143 -0.045
201909 -0.854 256.759 -1.098
201912 -0.648 256.974 -0.833
202003 -0.977 258.115 -1.250
202006 -0.808 257.797 -1.035
202009 0.195 260.280 0.247
202012 -1.019 260.474 -1.292
202103 -1.008 264.877 -1.257
202106 -1.129 271.696 -1.372
202109 -1.165 274.310 -1.402
202112 5.903 278.802 6.992
202203 -1.625 287.504 -1.866
202206 -1.495 296.311 -1.666
202209 -1.768 296.808 -1.967
202212 -1.303 296.797 -1.450
202303 -1.429 301.836 -1.563
202306 -1.532 305.109 -1.658
202309 -1.321 307.789 -1.417
202312 -1.302 306.746 -1.402
202403 -1.270 312.332 -1.343
202406 -0.975 314.175 -1.025
202409 -1.054 315.301 -1.104
202412 -0.965 315.605 -1.010
202503 0.111 319.799 0.115
202506 -1.196 322.561 -1.224
202509 -1.022 324.800 -1.039
202512 -1.110 324.054 -1.131
202603 -1.488 330.213 -1.488

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-2.51 mean?
Regenxbio (FRA:RB0) has a E10 of €-2.51 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Regenxbio and its competitors.
Is Regenxbio's E10 too high?
Regenxbio's current E10 is €-2.51. Overall, Regenxbio has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Regenxbio's E10 compare to ALT and ASMB?
Regenxbio's E10 of €-2.51 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Regenxbio and its competitors. Regenxbio's current E10 is €-2.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenxbio stock overvalued right now?
Based on GuruFocus' analysis, Regenxbio (FRA:RB0) is currently considered Fairly Valued. The stock's GF Value™ is €12.61, compared to a current price of €13.00 — trading 3.1% above its estimated fair value. The current E10 is €-2.51. Regenxbio's overall GF Score™ is 55/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Regenxbio (FRA:RB0), the current E10 is €-2.51 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Regenxbio (FRA:RB0) Overvalued in 2026?

Based on GuruFocus' analysis, Regenxbio stock appears to be overvalued. The current stock price of €13.00 is trading 3.1% above its estimated GF Value™ of €12.61. GuruFocus considers Regenxbio to be Fairly Valued.

Key valuation signals for FRA:RB0:

  • E10: €-2.51
  • GF Value™: €12.61 vs. price of €13.00 (3.1% above fair value)
  • GF Score™: 55/100 with 9 warning signs

No single metric tells the full story. See the FRA:RB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Regenxbio Business Description

Other Exchanges RGNX:USARB0:Germany
Address 9804 Medical Center Drive, Rockville, MD, USA, 20850
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
55GF Score

Get the complete analysis for FRA:RB0

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.00
Price
€12.61
GF Value